{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.0","upperLimit":"39.2","value":"26.5"},{"groupId":"OG001","lowerLimit":"9.9","upperLimit":"29.7","value":"18.8"},{"groupId":"OG002","lowerLimit":"23.1","upperLimit":"46.7","value":"34.4"},{"groupId":"OG003","lowerLimit":"27.1","upperLimit":"52.2","value":"39.2"},{"groupId":"OG004","lowerLimit":"6.5","upperLimit":"18.8","value":"12.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"98"}],"units":"Participants"}],"description":"ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \\* 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.","dispersionType":"95% Confidence Interval","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"1 mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG004","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received study drug in Part A. Participants who had missing components of the ACR50 index at analysis time point had these components imputed by LOCF.","reportingStatus":"POSTED","timeFrame":"Baseline through Week 12","title":"Percentage of Participants Who Achieved an ACR50 Response Baseline Through Week 12 - Model Based Dose Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}